$IPSC News

Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation

Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813

Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics Announces Presentation Of New Preclinical Data At American Diabetes Association Sessions Supporting CNTY-813 Novel Islet Cell Replacement Treatment

Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

Century Therapeutics Reports First Quarter Financial Results and Business Updates

Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate

H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions